

SELECTED REFERENCES

- Aaronson, N., et al. (1993). "The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology." *Journal of the National Cancer Institute* 85: 365-376.
- Anota, A., et al. (2017). "QoLR: Package for the Longitudinal Analysis of Health-Related Quality of Life in Oncology." *Journal of Statistical Software* 77(12): 1-30.
- Anwar, S., et al. (2014). "Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial." *J Gastrointest Oncol* 5(6): 433-439.
- Awad, L., et al. (2002). *Applying Survival Data Methodology to Analyze Longitudinal Quality of Life Data. Statistical Methods for Quality of Life Studies.* C. B. F. Mesbah M., Lee ML.T. Boston, MA, Springer: 231-243.
- Bonnetain, F., et al. (2010). "Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma." *Eur J Cancer* 46(15): 2753-2762.
- Chiorean, E. G. and A. L. Covelev (2015). "Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies." *Drug Des Devel Ther* 9: 3529-3545.
- Cocks, K., et al. (2008). "Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials." *Eur J Cancer* 44(13): 1793-1798.
- Conroy, T., et al. (2011). "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer." *N Engl J Med* 364(19): 1817-1825.
- Conroy, T., et al. (2013). "The role of the FOLFIRINOX regimen for advanced pancreatic cancer." *Current Oncology Reports* 15(2): 182-189.
- Donneau, A. F., et al. (2014). "Longitudinal quality of life data: a comparison of continuous and ordinal approaches." *Qual Life Res* 23(10): 2873-2881.
- Ediebah, D. E., et al. (2015). "Joint modeling of longitudinal health-related quality of life data and survival." *Qual Life Res* 24(4): 795-804.
- Goldstein, D., et al. (2015). "nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial." *J Natl Cancer Inst* 107(2).
- Gourgou-Bourgade, S., et al. (2013). "Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial." *J Clin Oncol* 31(1): 23-29.
- Maringwa, J. T., et al. (2011). "Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials." *Support Care Cancer* 19(11): 1753-1760.

Montazeri, A. (2009). "Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008." *Health Qual Life Outcomes* 7: 102.

Ousmen, A., et al. (2016). "Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time." *Health Qual Life Outcomes* 14(1): 167.

Quinten, C., et al. (2009). "Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials." *The Lancet Oncology* 10(9): 865-871.

Quinten, C., et al. (2011). "Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival." *J Natl Cancer Inst* 103(24): 1851-1858.

Quinten, C., et al. (2014). "A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites." *Cancer* 120(2): 302-311.

Ryan, D. P., et al. (2014). "Pancreatic adenocarcinoma." *N Engl J Med* 371(22): 2140-2141.

Sohal, D. P., et al. (2016). "Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline." *J Clin Oncol* 34(23): 2784-2796.

Sohal, D. P., et al. (2017). "Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary." *J Oncol Pract* 13(4): 261-264.

Sohal, D. P. S., et al. (2018). "Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update." *J Clin Oncol* 36(24): 2545-2556.

Von Hoff, D. D., et al. (2013). "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine." *N Engl J Med* 369(18): 1691-1703.

Von Hoff, D. D., et al. (2011). "Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial." *J Clin Oncol* 29(34): 4548-4554.